Sljivancanin Jakovljevic, Tamara (57207933278)Tamara (57207933278)Sljivancanin JakovljevicKontic-Vucinic, Olivera (16063770000)Olivera (16063770000)Kontic-VucinicNikolic, Nadja (55324775800)Nadja (55324775800)NikolicCarkic, Jelena (55802211000)Jelena (55802211000)CarkicMilasin, Jelena (6603015594)Jelena (6603015594)Milasin2025-06-122025-06-122020https://doi.org/10.1080/10641955.2020.1843663https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095822671&doi=10.1080%2f10641955.2020.1843663&partnerID=40&md5=d5156bab59555c2fae38105834756c41https://remedy.med.bg.ac.rs/handle/123456789/4667Objectives: Establishment of association between: (a) Val158Met COMT (G1947A) polymorphism and preeclampsia; (b) cytokines gene expression and COMT genotypes. Methods: 50 preeclampsia and 50 healthy pregnant women were enrolled. COMT genotyping was done by PCR/RFLP. TNF-α, IL-1β, and IL-6 mRNA levels were determined by Real-time PCR. Results: Variant (AA) homozygotes carried 3.7-fold increased preeclampsia odds, especially for severe (OR = 9.0, 95%CI (2.09–38.799)) and early forms (OR = 6.6, 95%CI (1.62–26.87)). AA homozygotes with PE had higher TNF-α levels compared to controls (P = 0.012). Conclusions: Val158Met COMT polymorphism increases preeclampsia risk. TNF-α expression and Val158Met COMT polymorphism have concomitant roles in PE pathogenesis. © 2020 Informa UK Limited, trading as Taylor & Francis Group.catechol O-methyltransferasecytokinespolymorphismPre-eclampsia